Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 11/2010

01.11.2010 | 2010 SSAT Poster Presentation

Surgical Resection and Multidisciplinary Care for Primary and Metastatic Pancreatic Islet Cell Carcinomas

verfasst von: Shaun McKenzie, Wendy Lee, Avo Artinyan, Brian Mailey, Alessio Pigazzi, Joshua Ellenhorn, Joseph Kim

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The role of multidisciplinary management of islet cell cancers (ICC) has not been fully investigated in a population-based setting.

Methods

The Los Angeles County Cancer Surveillance Program was assessed for patients with ICC between the years 1982 to 2006. Patients were stratified by treatment received and clinicopathologic characteristics and survival were compared.

Results

We identified 236 patients with ICC; 86 patients underwent curative-intent surgery with median survival for local, regional, and distant disease of 17.3, 12.2, and 4.0 years, respectively. In comparison, 102 patients underwent medical management alone; survival was significantly shorter when compared to the surgical cohort for local, regional, and distant disease (p < 0.05). To determine whether adjuvant chemotherapy was associated with improved survival, we compared patients who underwent surgery alone compared to patients who underwent surgery followed by adjuvant chemotherapy. Although patients with metastatic disease had 3-year longer survival with adjuvant chemotherapy, these improvements in survival were not statistically significant.

Conclusion

Surgical resection was associated with improved survival compared to medical management for any extent of disease in patients with ICC. Furthermore, adjuvant chemotherapy was not associated with survival but does warrant further examination in patients with metastatic disease.
Literatur
1.
Zurück zum Zitat Capelli P, Martigoni G, Pedica F, Falconi M, Antonello D, Malpeli G, Scarpa A. Endocrine neoplasms of the pancreas: pathologic and genetic factors. Arch Pathol Lab Med 2009;133(3):350–364.PubMed Capelli P, Martigoni G, Pedica F, Falconi M, Antonello D, Malpeli G, Scarpa A. Endocrine neoplasms of the pancreas: pathologic and genetic factors. Arch Pathol Lab Med 2009;133(3):350–364.PubMed
2.
Zurück zum Zitat O’Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. EJSO 2008;34(3):324–332.PubMed O’Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. EJSO 2008;34(3):324–332.PubMed
3.
Zurück zum Zitat Ehehalt F, Saeger H, Schmidt M, Grutzmann R. Neuroendocrine tumors of the Pancreas. Oncologist 2009;14(5):456–467.CrossRefPubMed Ehehalt F, Saeger H, Schmidt M, Grutzmann R. Neuroendocrine tumors of the Pancreas. Oncologist 2009;14(5):456–467.CrossRefPubMed
4.
Zurück zum Zitat Hochwald S, Zee S, Conlon K, Colleoni R, Louie O, Brennan M, Klimstra D. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20(11):2633–2642.CrossRefPubMed Hochwald S, Zee S, Conlon K, Colleoni R, Louie O, Brennan M, Klimstra D. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20(11):2633–2642.CrossRefPubMed
5.
Zurück zum Zitat Abood G, Go A, Malhotra D, Shoup M. The surgical and systematic management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2009;89(1):249–266.CrossRefPubMed Abood G, Go A, Malhotra D, Shoup M. The surgical and systematic management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2009;89(1):249–266.CrossRefPubMed
6.
Zurück zum Zitat Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Bulcher M. Clinical outcome and long term survival in 118 consecutive patients with neuroendocrine tumors of the pancreas. Br J Surg 2008;95(5):627–635.CrossRefPubMed Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Bulcher M. Clinical outcome and long term survival in 118 consecutive patients with neuroendocrine tumors of the pancreas. Br J Surg 2008;95(5):627–635.CrossRefPubMed
7.
Zurück zum Zitat Schurr P, Strate T, Rese K, Kaifi J, Reichelt U, Petri S, Kleinhans H, Yekebas E, Izbicki J. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumours: an institutional experience. Ann Surg 2007;245(2):273–281.CrossRefPubMed Schurr P, Strate T, Rese K, Kaifi J, Reichelt U, Petri S, Kleinhans H, Yekebas E, Izbicki J. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumours: an institutional experience. Ann Surg 2007;245(2):273–281.CrossRefPubMed
8.
Zurück zum Zitat Teh S, Deveney C, Sheppard B. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg 2007;193(5):610–613.CrossRefPubMed Teh S, Deveney C, Sheppard B. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg 2007;193(5):610–613.CrossRefPubMed
9.
Zurück zum Zitat You DD, Lee HG, Pail HG, Heo JS, Choi SH, Choi DW. The outcomes after surgical resection in pancreatic endocrine tumors: an institutional experience. EJSO 2009;35(7):728–733.PubMed You DD, Lee HG, Pail HG, Heo JS, Choi SH, Choi DW. The outcomes after surgical resection in pancreatic endocrine tumors: an institutional experience. EJSO 2009;35(7):728–733.PubMed
10.
Zurück zum Zitat Nguyen S, Angel L, Divino C, Schluender S, Warner R. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 2007;96(5):397–403.CrossRefPubMed Nguyen S, Angel L, Divino C, Schluender S, Warner R. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 2007;96(5):397–403.CrossRefPubMed
11.
Zurück zum Zitat Hodul P, Strosberg J, Kvols L. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 2008;15(4):314–321.PubMed Hodul P, Strosberg J, Kvols L. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 2008;15(4):314–321.PubMed
12.
Zurück zum Zitat Yao J, Eisner M, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans D. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14(12):3492–3500.CrossRefPubMed Yao J, Eisner M, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans D. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14(12):3492–3500.CrossRefPubMed
13.
Zurück zum Zitat Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, Blumgart L. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190(4):432–445.CrossRefPubMed Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, Blumgart L. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190(4):432–445.CrossRefPubMed
14.
Zurück zum Zitat Kim J, Sun C, Mailey B, Prendergast C, Artinyan A, Bhatia S, Pigazzi A, Ellenhorn J. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 2010;21:152–160.CrossRefPubMed Kim J, Sun C, Mailey B, Prendergast C, Artinyan A, Bhatia S, Pigazzi A, Ellenhorn J. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 2010;21:152–160.CrossRefPubMed
15.
Zurück zum Zitat Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave G, Panzuto F, Scarpa A, Falconi M. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumors. Ann Oncol 2008;13(5):903–908.CrossRef Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave G, Panzuto F, Scarpa A, Falconi M. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumors. Ann Oncol 2008;13(5):903–908.CrossRef
16.
Zurück zum Zitat Liang H, Wang P, Wang X, Wang J, Hao X. Management of nonfunctioning islet cell tumors. World J Gastroenterol 2004;10(12):1806–1809.PubMed Liang H, Wang P, Wang X, Wang J, Hao X. Management of nonfunctioning islet cell tumors. World J Gastroenterol 2004;10(12):1806–1809.PubMed
17.
Zurück zum Zitat Hill J, McPhee J, McDade T, Zhou Z, Sullivan M, Whalen G, Tseng J. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009;115(4):741–751.CrossRefPubMed Hill J, McPhee J, McDade T, Zhou Z, Sullivan M, Whalen G, Tseng J. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009;115(4):741–751.CrossRefPubMed
18.
Zurück zum Zitat Bilimoria K, Talamonti M, Tomlinson J, Stewart A, Winchester D, Ko C, Bentrem D. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008;247(3):490–500.CrossRefPubMed Bilimoria K, Talamonti M, Tomlinson J, Stewart A, Winchester D, Ko C, Bentrem D. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008;247(3):490–500.CrossRefPubMed
19.
Zurück zum Zitat Chung J, Choi D, Jo S, Heo J, Choi S, Kim Y. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment. World J Surg 2007;31(3):579–585.CrossRefPubMed Chung J, Choi D, Jo S, Heo J, Choi S, Kim Y. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment. World J Surg 2007;31(3):579–585.CrossRefPubMed
20.
Zurück zum Zitat Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P, Falconi M. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009;41(1):49–55.CrossRefPubMed Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P, Falconi M. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009;41(1):49–55.CrossRefPubMed
21.
Zurück zum Zitat Bloomston M, Muscarella P, Shah M, Frankel W, Al-Saif O, Martin E, Ellison E. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 2006;10(10):1361–1370.CrossRefPubMed Bloomston M, Muscarella P, Shah M, Frankel W, Al-Saif O, Martin E, Ellison E. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 2006;10(10):1361–1370.CrossRefPubMed
22.
Zurück zum Zitat House M, Cameron J, Lillemoe K, Schulick R, Choti M, Hansel D, Hruban R, Maitra A, Yeo C. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 2006;10(1):138–145.CrossRefPubMed House M, Cameron J, Lillemoe K, Schulick R, Choti M, Hansel D, Hruban R, Maitra A, Yeo C. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 2006;10(1):138–145.CrossRefPubMed
23.
Zurück zum Zitat Norton J, Warren R, Kelly M, Zuraek M, Jensen R. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134(6):1057–1063.CrossRefPubMed Norton J, Warren R, Kelly M, Zuraek M, Jensen R. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134(6):1057–1063.CrossRefPubMed
24.
Zurück zum Zitat Kaltsas G, Besser M, Grossman A. The diagnosis and management of advanced neuroendocrine tumors. Endocrine Rev 2004;25(3):458–511.CrossRefPubMed Kaltsas G, Besser M, Grossman A. The diagnosis and management of advanced neuroendocrine tumors. Endocrine Rev 2004;25(3):458–511.CrossRefPubMed
25.
Zurück zum Zitat Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Ann Oncol 2001;12(S2):S111–S114.CrossRefPubMed Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Ann Oncol 2001;12(S2):S111–S114.CrossRefPubMed
26.
Zurück zum Zitat Strosberg J, Kvols L. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007;16(2):219–214.CrossRefPubMed Strosberg J, Kvols L. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007;16(2):219–214.CrossRefPubMed
27.
Zurück zum Zitat Maire F, Hammel P, Kianmanesh R, Hentic O, Couvelard A, Rebours V, Zappa M, Raymond E, Sauvanet A, Louvet C, Levy P, Belghiti J, Ruszniewski P. Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 2009;145(1):69–75.CrossRefPubMed Maire F, Hammel P, Kianmanesh R, Hentic O, Couvelard A, Rebours V, Zappa M, Raymond E, Sauvanet A, Louvet C, Levy P, Belghiti J, Ruszniewski P. Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 2009;145(1):69–75.CrossRefPubMed
28.
Zurück zum Zitat Frank M, Klose K, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and α-interferon: effect of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94(5):1381–1387.PubMed Frank M, Klose K, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and α-interferon: effect of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94(5):1381–1387.PubMed
29.
Zurück zum Zitat Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday T. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005;80(4):502–506.CrossRefPubMed Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday T. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005;80(4):502–506.CrossRefPubMed
30.
Zurück zum Zitat Faiss S, Pape U, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken E, Wiedenmann B, International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21(14):2689–2696.CrossRefPubMed Faiss S, Pape U, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken E, Wiedenmann B, International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21(14):2689–2696.CrossRefPubMed
Metadaten
Titel
Surgical Resection and Multidisciplinary Care for Primary and Metastatic Pancreatic Islet Cell Carcinomas
verfasst von
Shaun McKenzie
Wendy Lee
Avo Artinyan
Brian Mailey
Alessio Pigazzi
Joshua Ellenhorn
Joseph Kim
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 11/2010
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1225-8

Weitere Artikel der Ausgabe 11/2010

Journal of Gastrointestinal Surgery 11/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.